Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Canadian Filing of NDS for Preservative - Free Glaucoma Medication","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Mr. Doug Janzen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Announces Financing to Support Launch of Zimed\u00ae Preservative - Free (Bimatoprost 0.03%) and Board Update","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed\u00ae PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Aequus Pharmaceuticals

    Menu

    Aequus Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aequus Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aequus Announces Financing to Support Launch of Zimed® Preservative - Free (Bimatoprost 0.03%) and Board Update

              Details:

              The net proceeds from the financing will be used to support the launch of Zimed PF (bimatoprost) for the reduction of elevated intraocular pressure (IOP) in patients with open - angled glaucoma or ocular hypertension.

              Lead Product(s): Bimatoprost

              Therapeutic Area: Ophthalmology Product Name: Zimed PF

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Mr. Doug Janzen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing April 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aequus Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF (Preservative Free)

              Details:

              Zimed PF (bimatoprost) a preservative-free, ophthalmic solution, is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.

              Lead Product(s): Bimatoprost

              Therapeutic Area: Ophthalmology Product Name: Zimed PF

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sandoz B2B

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aequus Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)

              Details:

              Under the agreement, Sandoz gained access to both Vistitan and Tacrolimus IR. Vistitan (bimatoprost) is a prostaglandin for IOP lowering in patients with open-angle glaucoma or ocular hypertension.

              Lead Product(s): Bimatoprost

              Therapeutic Area: Ophthalmology Product Name: Vistitan

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sandoz B2B

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aequus Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada

              Details:

              Under the agreement, Sandoz gained access to both Vistitan and Tacrolimus IR. Vistitan (bimatoprost) is a prostaglandin for IOP lowering in patients with open-angle glaucoma or ocular hypertension.

              Lead Product(s): Bimatoprost

              Therapeutic Area: Ophthalmology Product Name: Vistitan

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sandoz B2B

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aequus Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aequus Announces Canadian Filing of NDS for Preservative - Free Glaucoma Medication

              Details:

              Zimed PF (bimatoprost) a preservative-free, ophthalmic solution, is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.

              Lead Product(s): Bimatoprost

              Therapeutic Area: Ophthalmology Product Name: Zimed PF

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aequus Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada

              Details:

              Aequus has agreed to an extension of terms for its promotional service agreement with Sandoz Canada Inc. on tacrolimus immediate-release Tacrolimus IR to December 31st, 2021.

              Lead Product(s): Tacrolimus

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sandoz B2B

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY